中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 5
May  2026
Turn off MathJax
Article Contents

Ferroptosis in alcoholic liver fibrosis: Mechanism of action and therapeutic strategies

DOI: 10.12449/JCH260525
Research funding:

National Natural Science Foundation of China (82160303);

Key R&D Project in Hainan Province (ZDYF2021SHFZ050)

More Information
  • Corresponding author: WU Tao, wutao1_ren@163.com (ORCID: 0000-0002-3887-645X)
  • Received Date: 2026-02-09
  • Accepted Date: 2026-02-24
  • Published Date: 2026-05-25
  • Alcoholic liver fibrosis is a critical step in the progression of alcoholic liver disease toward liver cirrhosis, yet there is currently still a lack of effective and specific anti-fibrotic therapeutic strategies. Recent studies have shown that as an iron-dependent, lipid peroxidation-driven form of regulated cell death, ferroptosis plays an important role in alcohol-related hepatocellular injury and fibrogenesis. Reactive oxygen species generated during alcohol metabolism can damage hepatocytes, impair their antioxidant defense ability, and lead to disruption of iron homeostasis and accumulation of lipid peroxides, ultimately triggering ferroptosis. Hepatocyte ferroptosis can promote fibrosis by amplifying inflammatory responses and activating hepatic stellate cells, whereas selective induction of ferroptosis in activated hepatic stellate cells may attenuate fibrosis, highlighting the “double-edged sword” effect of ferroptosis. Current interventions against ferroptosis mainly focus on applying antioxidant approaches, reducing iron burden, or blocking the amplification of lipid peroxidation, which have shown preliminary efficacy and a potential clinical value, but there are still limitations such as single-target actions and insufficient cell selectivity. In the future, nanotechnology-based delivery and other targeting strategies may help to realize multi-pathway coordination and cell-specific modulation, thereby improving the anti-fibrotic efficacy of ferroptosis-oriented therapies.

     

  • loading
  • [1]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 939- 946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 939- 946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.
    [2]
    FENG XF, HUANG NF, WU YQ, et al. Alcoholic liver disease in China: A disease influenced by complex social factors that should not be neglected[J]. J Clin Transl Hepatol, 2024, 12( 7): 677- 684. DOI: 10.14218/JCTH.2024.00034.
    [3]
    ALI N, FERRAO K, MEHTA KJ. Liver iron loading in alcohol-associated liver disease[J]. Am J Pathol, 2023, 193( 10): 1427- 1439. DOI: 10.1016/j.ajpath.2022.08.010.
    [4]
    SU LJ, ZHANG JH, GOMEZ H, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis[J]. Oxid Med Cell Longev, 2019, 2019: 5080843. DOI: 10.1155/2019/5080843.
    [5]
    GANZ T, NEMETH E. Hepcidin and iron homeostasis[J]. Biochim Biophys Acta BBA Mol Cell Res, 2012, 1823( 9): 1434- 1443. DOI: 10.1016/j.bbamcr.2012.01.014.
    [6]
    LIM D, KIM KS, JEONG JH, et al. The hepcidin-ferroportin axis controls the iron content of Salmonella-containing vacuoles in macrophages[J]. Nat Commun, 2018, 9( 1): 2091. DOI: 10.1038/s41467-018-04446-8.
    [7]
    ZHANG WL, ZHONG W, SUN Q, et al. Hepatic overproduction of 13-HODE due to ALOX15 upregulation contributes to alcohol-induced liver injury in mice[J]. Sci Rep, 2017, 7( 1): 8976. DOI: 10.1038/s41598-017-02759-0.
    [8]
    KAGAN VE, MAO GW, QU F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis[J]. Nat Chem Biol, 2017, 13( 1): 81- 90. DOI: 10.1038/nchembio.2238.
    [9]
    HOWARTH DL, VACARU AM, TSEDENSODNOM O, et al. Alcohol disrupts endoplasmic reticulum function and protein secretion in hepatocytes[J]. Alcohol Clin Exp Res, 2012, 36( 1): 14- 23. DOI: 10.1111/j.1530-0277.2011.01602.x.
    [10]
    LUO J, SONG G, CHEN NN, et al. Ferroptosis contributes to ethanol-induced hepatic cell death via labile iron accumulation and GPx4 inactivation[J]. Cell Death Discov, 2023, 9( 1): 311. DOI: 10.1038/s41420-023-01608-6.
    [11]
    THOUDAM T, GAO H, JIANG YC, et al. Mitochondrial quality control in alcohol-associated liver disease[J]. Hepatol Commun, 2024, 8( 11): e0534. DOI: 10.1097/HC9.0000000000000534.
    [12]
    YANG WS, SRIRAMARATNAM R, WELSCH ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156( 1-2): 317- 331. DOI: 10.1016/j.cell.2013.12.010.
    [13]
    FRIEDMANN ANGELI JP, SCHNEIDER M, PRONETH B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J]. Nat Cell Biol, 2014, 16( 12): 1180- 1191. DOI: 10.1038/ncb3064.
    [14]
    BRIDGES RJ, NATALE NR, PATEL SA. System xc cystine/glutamate antiporter: An update on molecular pharmacology and roles within the CNS[J]. Br J Pharmacol, 2012, 165( 1): 20- 34. DOI: 10.1111/j.1476-5381.2011.01480.x.
    [15]
    XIE YC, ZHU S, SONG XX, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity[J]. Cell Rep, 2017, 20( 7): 1692- 1704. DOI: 10.1016/j.celrep.2017.07.055.
    [16]
    LIU YQ, GU W. p53 in ferroptosis regulation: The new weapon for the old guardian[J]. Cell Death Differ, 2022, 29( 5): 895- 910. DOI: 10.1038/s41418-022-00943-y.
    [17]
    ROUAULT TA. Hepatic iron overload in alcoholic liver disease: Why does it occur and what is its role in pathogenesis?[J]. Alcohol, 2003, 30( 2): 103- 106. DOI: 10.1016/s0741-8329(03)00102-2.
    [18]
    OHTAKE T, SAITO H, HOSOKI Y, et al. Hepcidin is down-regulated in alcohol loading[J]. Alcohol Clin Exp Res, 2007, 31( 1 Suppl): S2- S8. DOI: 10.1111/j.1530-0277.2006.00279.x.
    [19]
    ZHOU Z, YE TJ, DECARO E, et al. Intestinal SIRT1 deficiency protects mice from ethanol-induced liver injury by mitigating ferroptosis[J]. Am J Pathol, 2020, 190( 1): 82- 92. DOI: 10.1016/j.ajpath.2019.09.012.
    [20]
    DIXON SJ, LEMBERG KM, LAMPRECHT MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149( 5): 1060- 1072. DOI: 10.1016/j.cell.2012.03.042.
    [21]
    LIU CY, WANG M, YU HM, et al. Ferroptosis is involved in alcohol-induced cell death in vivo and in vitro[J]. Biosci Biotechnol Biochem, 2020, 84( 8): 1621- 1628. DOI: 10.1080/09168451.2020.1763155.
    [22]
    LU YZ, HU JJ, CHEN L, et al. Ferroptosis as an emerging therapeutic target in liver diseases[J]. Front Pharmacol, 2023, 14: 1196287. DOI: 10.3389/fphar.2023.1196287.
    [23]
    CONRAD M, PRATT DA. The chemical basis of ferroptosis[J]. Nat Chem Biol, 2019, 15( 12): 1137- 1147. DOI: 10.1038/s41589-019-0408-1.
    [24]
    YANG WS, STOCKWELL BR. Ferroptosis: Death by lipid peroxidation[J]. Trends Cell Biol, 2016, 26( 3): 165- 176. DOI: 10.1016/j.tcb.2015.10.014.
    [25]
    WANG BQ, WANG Y, ZHANG J, et al. ROS-induced lipid peroxidation modulates cell death outcome: Mechanisms behind apoptosis, autophagy, and ferroptosis[J]. Arch Toxicol, 2023, 97( 6): 1439- 1451. DOI: 10.1007/s00204-023-03476-6.
    [26]
    ZHENG XG, JIN XD, YE F, et al. Ferroptosis: A novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy[J]. Exp Hematol Oncol, 2023, 12( 1): 65. DOI: 10.1186/s40164-023-00427-w.
    [27]
    IMAI H, MATSUOKA M, KUMAGAI T, et al. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis[M]// Apoptotic and Non-apoptotic Cell Death. Cham: Springer International Publishing, 2016: 143- 170. DOI: 10.1007/82_2016_508.
    [28]
    LV YH, WU MY, WANG Z, et al. Ferroptosis: From regulation of lipid peroxidation to the treatment of diseases[J]. Cell Biol Toxicol, 2023, 39( 3): 827- 851. DOI: 10.1007/s10565-022-09778-2.
    [29]
    LYAMZAEV KG, PANTELEEVA AA, SIMONYAN RA, et al. The critical role of mitochondrial lipid peroxidation in ferroptosis: Insights from recent studies[J]. Biophys Rev, 2023, 15( 5): 875- 885. DOI: 10.1007/s12551-023-01126-w.
    [30]
    SUN LJ, CAO HF, WANG YZ, et al. Regulating ferroptosis by non-coding RNAs in hepatocellular carcinoma[J]. Biol Direct, 2024, 19( 1): 80. DOI: 10.1186/s13062-024-00530-w.
    [31]
    GAO H, JIN ZM, BANDYOPADHYAY G, et al. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis[J]. Cell Metab, 2022, 34( 8): 1201- 1213. e 5. DOI: 10.1016/j.cmet.2022.07.006.
    [32]
    HUANG Q, WANG ZY, AN ZM, et al. Effect of NOD-like receptor family pyrin domain containing 3 knockdown on a mouse model of nonalcoholic steatohepatitis induced by high-fat high-carbohydrate diet[J]. J Clin Hepatol, 2024, 40( 5): 952- 960. DOI: 10.12449/JCH240514.

    黄倩, 王卓媛, 安梓铭, 等. NLRP3基因敲减对高脂高糖饮食诱导的非酒精性脂肪性肝炎小鼠模型的影响[J]. 临床肝胆病杂志, 2024, 40( 5): 952- 960. DOI: 10.12449/JCH240514.
    [33]
    GAO B, BATALLER R. Alcoholic liver disease: Pathogenesis and new therapeutic targets[J]. Gastroenterology, 2011, 141( 5): 1572- 1585. DOI: 10.1053/j.gastro.2011.09.002.
    [34]
    WANG H, WANG HT, XIU TC, et al. A"cocktail" fluorescent probe for multi-ROS imaging unveils ferroptosis-driven liver fibrosis development[J]. Angew Chem Int Ed, 2025, 64( 35): e202506728. DOI: 10.1002/anie.202506728.
    [35]
    LAI WJ, WANG B, HUANG RS, et al. Ferroptosis in organ fibrosis: From mechanisms to therapeutic medicines[J]. J Transl Int Med, 2024, 12( 1): 22- 34. DOI: 10.2478/jtim-2023-0137.
    [36]
    FALLOWFIELD JA, JIMENEZ-RAMOS M, ROBERTSON A. Emerging synthetic drugs for the treatment of liver cirrhosis[J]. Expert Opin Emerg Drugs, 2021, 26( 2): 149- 163. DOI: 10.1080/14728214.2021.1918099.
    [37]
    ZHOU XX, FU YD, CHEN JM, et al. Progress in clinical and basic research of fuzheng Huayu formula for the treatment of liver fibrosis[J]. J Ethnopharmacol, 2024, 327: 118018. DOI: 10.1016/j.jep.2024.118018.
    [38]
    LIU YQ, ZHANG C, LI JW, et al. An-Luo-Hua-Xian pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Clin Transl Hepatol, 2023, 11( 2): 304- 313. DOI: 10.14218/JCTH.2022.00091.
    [39]
    de ANDRADE KQ, MOURA FA, DOS SANTOS JM, et al. Oxidative stress and inflammation in hepatic diseases: Therapeutic possibilities of N-acetylcysteine[J]. Int J Mol Sci, 2015, 16( 12): 30269- 30308. DOI: 10.3390/ijms161226225.
    [40]
    ZHOU LF, XIAO M, LI YX, et al. Ursolic acid ameliorates alcoholic liver injury through attenuating oxidative stress-mediated ferroptosis and modulating gut microbiota[J]. J Agric Food Chem, 2024, 72( 38): 21181- 21192. DOI: 10.1021/acs.jafc.4c04762.
    [41]
    SHI JF, LIU YE, WANG Y, et al. Targeting ferroptosis, a novel programmed cell death, for the potential of alcohol-related liver disease therapy[J]. Front Pharmacol, 2023, 14: 1194343. DOI: 10.3389/fphar.2023.1194343.
    [42]
    LI X, TAO L, ZHONG MJ, et al. Ferroptosis and liver diseases[J]. J Zhejiang Univ Med Sci, 2024, 53( 6): 747- 755. DOI: 10.3724/zdxbyxb-2024-0566.

    李欣, 陶亮, 钟美娟, 等. 铁死亡参与肝疾病研究进展[J]. 浙江大学学报(医学版), 2024, 53( 6): 747- 755. DOI: 10.3724/zdxbyxb-2024-0566.
    [43]
    ZHOU XY, WANG JC, ZHOU SF. Poria cocos polysaccharides improve alcoholic liver disease by interfering with ferroptosis through NRF2 regulation[J]. Aging, 2024, 16( 7): 6147- 6162. DOI: 10.18632/aging.205693.
    [44]
    TONG J, LAN XT, ZHANG Z, et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: Potential involvement of PANoptosis[J]. Acta Pharmacol Sin, 2023, 44( 5): 1014- 1028. DOI: 10.1038/s41401-022-01010-5.
    [45]
    PINYOPORNPANISH K, TANTIWORAWIT A, LEERAPUN A, et al. Secondary iron overload and the liver: A comprehensive review[J]. J Clin Transl Hepatol, 2023, 11( 4): 932- 941. DOI: 10.14218/JCTH.2022.00420.
    [46]
    LIU MX, CAI YT, WANG RJ, et al. Aggregation-induced emission CN-based nanoparticles to alleviate hypoxic liver fibrosis via triggering HSC ferroptosis and enhancing photodynamic therapy[J]. ACS Appl Mater Interfaces, 2024, 16( 26): 33021- 33037. DOI: 10.1021/acsami.4c04361.
    [47]
    YU YL, ZHANG SL, XU YF, et al. Oral delivery of ferroptosis inducers for effective treatment of hepatic fibrosis[J]. Nano Res, 2024, 17( 8): 7621- 7630. DOI: 10.1007/s12274-024-6725-z.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Article Metrics

    Article views (27) PDF downloads(9) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return